Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Futures Kickoff
Get prepared for your futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to experience risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q4 2025 Earnings Call Transcript
Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q4 and full-year 2025 financial results, with total revenue reaching $3.2 billion in Q4, a 10% increase year-over-year, and $12 billion for the full year, growing 9%. The company discussed strong performance in its CF franchise, successful launches of KASJEVY and Gernavix, and progress in its emerging renal pipeline, particularly with Povatacept for IgA nephropathy. Vertex provided 2026 revenue guidance of $12.95 billion to $13.1 billion, expecting significant contributions from non-CF products.